ERBB2 and gastric cancer: Above all, HER2 has been widely accepted as an underlying treatment biomarker of gastric cancer, and anti-HER2 therapy with the monoclonal antibody trastuzumab is recommended as the first-line therapy for patients with HER2-positive advanced or metastatic gastric cancer.